BridgeBio Strikes U.S. Government Deal to Expand Medicaid Access, Lower Drug Costs
Event summary
- BridgeBio Pharma entered a voluntary agreement with the U.S. government to expand Medicaid access to its rare disease treatments and lower drug costs.
- Attruby®, BridgeBio’s transthyretin stabilizer for ATTR-CM, will be available via the GENEROUS Model for Medicaid patients.
- The agreement exempts BridgeBio from future pricing mandates for Attruby® under Medicare Part D.
- BridgeBio’s ForgingBridges® copay assistance program will continue to offer $0 out-of-pocket costs for qualifying patients.
- The deal aims to balance affordability with sustained investment in rare disease innovation.
The big picture
BridgeBio’s agreement with the U.S. government reflects a broader trend of biopharma companies navigating regulatory pressures to lower drug costs while maintaining innovation in rare disease treatments. The deal underscores the growing importance of government partnerships in shaping drug pricing and access, particularly for conditions with limited treatment options. With three additional medicines under FDA review, BridgeBio’s ability to sustain its business model under this new framework will be closely watched.
What we're watching
- Regulatory Compliance
- Whether BridgeBio can maintain its exemption from future pricing mandates while expanding Medicaid access.
- Market Impact
- How this agreement influences other biopharma companies negotiating drug pricing with the U.S. government.
- Innovation Sustainability
- The pace at which BridgeBio can balance cost reductions with continued investment in rare disease drug development.